**Table 5:** Growth inhibition zones of the clinical isolates of pathogenic fungi under the action of the culture liquid (CL) of the strain *B. subtilis* 534 (diameters in mm).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Species, strains** | **Growth inhibition zones of CL, mm** | **Medical antimycotics\*** | | | | | |
| **Pyrimidine** | **Polyene** | **Imidazoles** | | **Triazoles** | |
| **5 FC** | **AB** | **MCZ** | **KET** | **ITR** | **FLU** |
| *Сandida albicans* 58 | 18 | S | R | R | R | R | R |
| *С. albicans* 182 | 19 | S | S | S | S | S | S |
| *С. albicans* 265 | 29 | S | R | S | S | I | S |
| *С. albicans* 317 | 20 | S | S | R | R | R | R |
| *С. albicans* 456 | 23 | S | R | I | I | I | S |
| *С. albicans* 458 | 17 | S | R | R | R | R | R |
| *С. albicans* 848 | 28 | S | R | R | R | R | R |
| *С. albicans* 922 | 24 | S | I | R | R | R | R |
| *С. albicans* 1187 | 19 | S | I | I | S | I | S |
| *С. albicans* 1294 | 31 | S | R | R | R | R | R |
| *С. albicans* 1610 | 0 | S | S | R | I | S | S |
| *С. albicans*1815 | 36 | S | R | I | S | I | S |
| *С. albicans* 2122 | 0 | S | S | I | I | I | I |
| *С. albicans* 2356 | 12 | R | R | R | R | R | R |
| *C. albicans* 4166 | 25 | R | I | R | R | I | R |
| *C. albicans* 4244 | 25 | R | R | R | R | I | R |
| *C. albicans* 4438 | 24 | R | S | I | S | I | R |
| *C. albicans* 4895 | 24 | S | R | I | R | R | R |
| *C. albicans* 4897 | 24 | S | S | S | I | R | R |
| *C. albicans* 5228 | 14 | R | R | I | R | R | R |
| *C. albicans* 5721 | 24 | S | R | I | R | R | R |
| *C. albicans* 5963 | 18 | I | R | R | R | R | R |
| *C. albicans* 6107 | 17 | R | R | R | I | R | S |
| *C. catenulata* 1507 | 0 | R | I | I | I | I | R |
| *C. catenulata* 6093 | 0 | S | R | I | I | R | I |
| *C. glabrata* 13 | 0 | S | R | I | I | I | I |
| *С. glabrata* 212 | 18 | S | R | R | R | R | R |
| *C. krusei* 247 | 0 | S | S | R | S | I | S |
| *C. lusitaniae* 5254 | 22 | S | R | I | S | I | S |
| *C. parapsilosis* 1380 | 0 | R | S | S | S | I | S |
| *С. tropicalis* 455 | 0 | S | R | R | R | R | R |
| *Cryptococcus neoformans* 25 | 0 | S | R | I | I | R | I |
| *C. neoformans* 245 | 25 | R | R | S | I | I | I |
| *Prototheca* sp. 110\*\* | 27 | S | R | R | R | R | R |
| *Prototheca* sp. 1376 | 0 | R | S | S | S | I | S |
| *Prototheca* sp. 6017 | 0 | S | R | I | R | R | I |
| *Prototheca* sp. 6047 | 24 | S | R | R | R | R | R |
| *Trichosporon* sp. БМ1.5 | 24 | I | S | I | I | I | S |

\*Antimycotics: 5 FC: 5-flucytosine; AB: AmphotericinB; MCZ: Miconazole; KET: Ketoconazole; ITR: Itraconazole; FLU: Fluconazole; R: Resistance; I: Intermediate susceptibility; S: Susceptibility.

\*\*- representatives of the genus *Prototheca* are chlorophyll-free algae; antimycotics are used to treat *Prototheca* infections.